Compare · APTX vs NVO
APTX vs NVO
Side-by-side comparison of Aptinyx Inc. (APTX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both APTX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO carries a market cap of $180.22B.
- NVO has hit the wire 9 times in the past 4 weeks while APTX has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 2 for APTX).
- Company
- Aptinyx Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- -
- $180.22B
- 1M return
- -
- +5.96%
- 1Y return
- -
- -14.37%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 0
- 9
- Recent ratings
- 2
- 25
Aptinyx Inc.
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase I clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc; and with Rosalind Franklin University of Medicine and Science. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest APTX
- Tentarix Biotherapeutics Announces the Appointment of Andrew D. Kidd, MD, CFA, as CEO
- SEC Form SC 13G/A filed by Aptinyx Inc. (Amendment)
- Aptinyx Inc. filed SEC Form 8-K: Other Events
- Aptinyx Inc. filed SEC Form 8-K: Other Events
- SEC Form 25-NSE filed by Aptinyx Inc.
- Aptinyx Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form SC 13D/A filed by Aptinyx Inc. (Amendment)
- SEC Form DEF 14A filed by Aptinyx Inc.
- SEC Form S-8 POS filed by Aptinyx Inc.
- SEC Form RW filed by Aptinyx Inc.
Latest NVO
- Novo launches the new Novocare®: Free support program connects people with Wegovy® in addition to home delivery, everyday support, wellness partners and rewards
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S